Literature DB >> 1788167

Stereospecific high-performance liquid chromatographic assay of sotalol in plasma.

R A Carr1, R T Foster, N H Bhanji.   

Abstract

A convenient high-performance liquid chromatographic (HPLC) assay was developed for determination of sotalol (STL) enantiomers in plasma. Following addition of the internal standard (IS; racemic atenolol), enantiomers of STL and IS were extracted using ethyl acetate. After evaporation of the organic layer, samples were derivatized with a solution of S-(+)-1-(1-naphthyl)ethyl isocyanate (NEIC). The resulting diastereomers were chromatographed with normal-phase HPLC with chloroform:hexane:methanol [65:33:2 (v/v)] as the mobile phase at a flow rate of 2 ml/min. The fluorescence detection wavelength was set at 220 nm for excitation with no emission filter. The suitability of the assay for pharmacokinetic studies was determined by measuring STL enantiomers in the plasma of a healthy subject after administration of a single 160-mg oral, racemic dose of STL.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1788167     DOI: 10.1023/a:1015870805757

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  20 in total

1.  Stereospecific high-performance liquid chromatographic determination of tocainide.

Authors:  R A Carr; R T Foster; D Freitag; F M Pasutto
Journal:  J Chromatogr       Date:  1991-05-03

2.  Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: an overview.

Authors:  D E Drayer
Journal:  Clin Pharmacol Ther       Date:  1986-08       Impact factor: 6.875

3.  Separation and spectrofluorometric assay of the -adrenergic blocker sotalol from blood and urine.

Authors:  E R Garrett; K Schnelle
Journal:  J Pharm Sci       Date:  1971-06       Impact factor: 3.534

4.  High performance liquid chromatographic determination of the enantiomers of beta-adrenoceptor blocking agents in biological fluids. I: Studies with pindolol.

Authors:  P H Hsyu; K M Giacomini
Journal:  J Pharm Sci       Date:  1986-06       Impact factor: 3.534

5.  Stereospecific high-performance liquid chromatographic assay of acebutolol in human plasma and urine.

Authors:  M Piquette-Miller; R T Foster; F M Pasutto; F Jamali
Journal:  J Chromatogr       Date:  1990-03-16

6.  Liquid chromatographic determination of sotalol in plasma and urine employing solid-phase extraction and fluorescence detection.

Authors:  M J Bartek; M Vekshteyn; M P Boarman; D G Gallo
Journal:  J Chromatogr       Date:  1987-10-30

7.  Pharmacokinetics of acebutolol enantiomers in humans.

Authors:  M Piquette-Miller; R T Foster; C T Kappagoda; F Jamali
Journal:  J Pharm Sci       Date:  1991-04       Impact factor: 3.534

8.  High-performance liquid chromatographic method for the quantitative analysis of the aryloxypropanolamines propranolol, metoprolol and atenolol in plasma and tissue.

Authors:  H Winkler; W Ried; B Lemmer
Journal:  J Chromatogr       Date:  1982-03-12

9.  Quantitative liquid chromatographic determination of sotalol in human plasma.

Authors:  J M Poirier; P Jaillon; G Cheymol
Journal:  Ther Drug Monit       Date:  1986       Impact factor: 3.681

10.  Determination of sotalol in human body fluids for pharmacokinetic and toxicokinetic studies using high-performance liquid chromatography.

Authors:  W P Gluth; F Sörgel; B Gluth; J Braun; M Geldmacher-von Mallinckrodt
Journal:  Arzneimittelforschung       Date:  1988-03
View more
  4 in total

1.  Drug-disease interactions: reduced beta-adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat.

Authors:  K M Kulmatycki; K Abouchehade; S Sattari; F Jamali
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

Review 2.  Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.

Authors:  A Fitton; E M Sorkin
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

3.  Stereoselective disposition of (+/-)-sotalol at steady-state conditions.

Authors:  C Fiset; F Philippon; M Gilbert; J Turgeon
Journal:  Br J Clin Pharmacol       Date:  1993-07       Impact factor: 4.335

4.  Digging into Lipid Membrane Permeation for Cardiac Ion Channel Blocker d-Sotalol with All-Atom Simulations.

Authors:  Kevin R DeMarco; Slava Bekker; Colleen E Clancy; Sergei Y Noskov; Igor Vorobyov
Journal:  Front Pharmacol       Date:  2018-02-01       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.